ArticleArtificial organs2026
A Novel Chitosan-Modified PLA Doped n-HA Bone Scaffold.
Article in Artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Based on the principles of bionics, the hydrophilicity, bacteriostasis, and alkalinity of chitosan (CS) have been utilized to enhance the hydrophilic and antibacterial properties of a polylactic acid (PLA) bone scaffold. They also neutralize the acidity generated by its degradation. The incorporation of nano-hydroxyapatite (n-HA) effectively improves the osteogenic properties of PLA. The PLA-CS graft was first synthesized by grafting CS onto PLA using ferulic acid (FA), resulting in a CS-modified, PLA-doped n-HA (PLA-CS/n-HA) bone scaffold. The prepared PLA-CS/n-HA bone scaffold facilitated the formation of new bone and tissue attachment. More importantly, the acidity from PLA degradation in the PLA-CS/n-HA scaffold was alleviated to a certain extent. Its hydrophilicity and compressive strength were enhanced compared to the PLA bone scaffold, and its antibacterial activity was stronger against Staphylococcus aureus than against Escherichia coli. After a 12 h co-culture with the PLA-CS/n-HA bone scaffold, the relative adhesion rate of MC3T3-E1 cells was 118.95%. After 14 days of inducing MC3T3-E1 cells on the PLA-CS/n-HA bone scaffold, the MC3T3-E1 cells exhibited preliminary differentiation and alkaline phosphatase activity reached 1.23. The PLA-CS/n-HA bone scaffold received a cytotoxicity grade of class 0, indicating no cytotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.